Efficacy News and Research

RSS

New combination therapy improves outcomes in high-risk leukemia

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel combination therapy that significantly improves treatment outcomes and survival in patients with acute myeloid leukaemia (AML) with FLT3 gene mutations.

11 Jun 2026

Experimental vaccine protects against fentanyl and related opioids

Fentanyl and related variants of the synthetic opioid kill more Americans each year than car accidents and gun violence combined. In too-high doses, the drugs hijack brain chemistry and shut down the signals that control breathing.

11 Jun 2026

Self-help program improves mental health among displaced refugees

A simple self-help workbook paired with brief phone support can make a measurable difference to the mental health of displaced refugees, a new study has found.

11 Jun 2026

Leading AI models ace many vaccine questions but falter on clinical rules

A multilingual benchmark of 1,886 vaccine-related questions found that large language models answered most items accurately across English, Spanish, and Chinese. However, performance varied by vaccine type, language, and prompting method, with persistent errors in dosing, contraindications, age eligibility, and other clinically sensitive guidance.

11 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

FDA accepts immunotherapy drug for review in colon cancer treatment

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech's supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq®) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR).

11 Jun 2026

Metformin reduces long COVID risk according to ACTIV-6 clinical trial

New findings from the ACTIV-6 randomized clinical trial provide important confirmation of prior clinical trial results that metformin, a widely available and inexpensive medication with an established safety record, reduced the risk of clinician-diagnosed long COVID when started during acute COVID-19 infection.

11 Jun 2026

Intravenous statins during heart attack reduce cardiac muscle damage

Reducing the damage sustained by the heart during a myocardial infarction remains one of the major challenges in cardiology, even when the blocked coronary artery is reopened in a timely manner.

11 Jun 2026

Blood pressure control may be the key to optimizing stroke treatment after thrombectomy

Blood pressure management after thrombectomy for acute ischemic stroke may require a change in approach.

11 Jun 2026

Circadian clock protein BMAL1 enhances inflammatory responses in immune cells

Daily life is shaped by the solar day, influencing when we wake up, eat, work, and sleep. Inside the body, a similar internal timing system -present in nearly every cell- known as the circadian clock, synchronizes many biological functions such as sleep, metabolism, hormone release, and even the immune system's activity.

11 Jun 2026

Prospective study compares three robotic platforms for colon resection

Since the introduction of the Da Vinci robotic system, robot-assisted colon resection has gained popularity because of its the potential technical advantages.

11 Jun 2026

A hidden immune pathway may help explain why Alzheimer’s inflammation persists

Researchers found that KAT7 promotes CMPK2-driven mitochondrial DNA release in microglia, activating inflammatory cGAS-STING and NLRP3 pathways linked to Alzheimer’s disease.

11 Jun 2026

New study maps early genetic disruptions in Rett syndrome

To better understand what drives the emergence of symptoms in Rett syndrome, researchers at Baylor College of Medicine and the Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital took a closer look at brain cells in mice modeling Rett syndrome before symptoms appeared.

10 Jun 2026

New DNA tetrahedron nanostructures improve targeted cancer therapy delivery

Conventional cancer treatments, such as chemotherapy, often lack specificity and can damage both cancerous and healthy cells, leading to severe side effects.

10 Jun 2026

Critical Path Institute opens registration for 2026 Global Impact Conference

Critical Path Institute (C-Path) will host its 2026 Global Impact Conference (CGIC) this September at the Washington Marriott at Metro Center in Washington, D.C.

10 Jun 2026

Proactive brain training strengthens mental wellness before challenges arise

A new study recently published in the peer-reviewed journal Frontiers in Psychology challenges the traditional, reactive model of mental health care by demonstrating that proactive brain training can strengthen the human mind before mental health challenges take root.

10 Jun 2026

Short four-minute workout boosts quality of life for seniors

Just four minutes of daily strengthening exercise dramatically increases key factors in quality of life for aging adults, according to a new study led by researchers at Penn State College of Medicine.

10 Jun 2026

Apitegromab helps tirzepatide users lose fat while preserving lean mass

A phase 2 trial found that apitegromab plus tirzepatide reduced lean body mass loss by 1.9 kg compared with tirzepatide plus placebo after 24 weeks, while overall weight loss remained similar.

9 Jun 2026

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.

9 Jun 2026

Study identifies key protein driving colon cancer drug resistance

One of the most widely used chemotherapeutic agents for colorectal cancer is 5-fluorouracil (5-FU), a cornerstone treatment that has improved outcomes for countless patients.

9 Jun 2026